[LCID Study Number: 2018-059CIRB]
A021602: Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus (CABINET)
Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors
The purpose of this study is to compare any good and bad effects of using cabozantinib to using a placebo (a pill that contains no active drug). This study will allow the researchers to know whether treatment with cabozantinib is better, the same, or worse than placebo.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3055